Exploring the first conditionally approved oral canine lymphoma treatment
Anivive Lifesciences' Chief Commerical Officer Chad Todd, DVM, offers insight on Laverdia-CA1, the first conditionally approved oral treatment for canine lymphoma.
According to the Veterinary Centers of America, lymphoma accounts for 15% to 20% of new cancer diagnoses in dogs and is the most common in middle-aged dogs.
Veterinarians now have oral therapy in their arsenal for canine patients suffering from lymphoma. Laverdia-CA1, the first FDA conditionally approved oral treatment for canine lymphoma prevents certain proteins from leaving the nucleus of cancer cells, thus allowing the proteins to control the growth and prevent the spread of cancerous cells.
In an interview with dvm360®, Anivive Lifesciences' Chief Commerical Officer Chad Dodd, DVM, offers more insight into this relatively new and revolutionary treatment.
Newsletter
From exam room tips to practice management insights, get trusted veterinary news delivered straight to your inbox—subscribe to dvm360.
Torsemide for canine CHF: Emerging evidence and clinical benefits
June 5th 2025William Rausch, DVM, DACVIM (Cardiology), explains that torsemide offers at least equivalent efficacy to furosemide in canine CHF while significantly reducing short-term mortality/worsening events by approximately 50%.
Read More
